[1]袁志斌.89Sr及联合治疗转移性骨肿瘤的临床应用[J].国际放射医学核医学杂志,2005,29(2):53-56.
　YUAN Zhi-bin.The clinical application of strontium-89 concomitant use with other modalities in the treatment of bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2005,29(2):53-56.
点击复制

89Sr及联合治疗转移性骨肿瘤的临床应用(/HTML)
分享到：

《国际放射医学核医学杂志》[ISSN:1673-4114/CN:12-1381/R]

卷:
29
期数:
2005年第2期
页码:
53-56
栏目:
核医学
出版日期:
1900-01-01

文章信息/Info

Title:
The clinical application of strontium-89 concomitant use with other modalities in the treatment of bone metastases
作者:
袁志斌
200233 上海, 上海交通大学附属第六人民医院核医学科
Author(s):
YUAN Zhi-bin
Department of Nuclear Medicine, Shanghai Sixth People’s Hospital, Shanghai Jiao Tong University, Shanghai 200233, China
关键词:
锶放射性同位素; 骨转移; 阿霉素; 吉西他滨; 顺铂; 放射治疗; 药物疗法; 联合
Keywords:
strontium radioisotope; bone metastases; doxorubicin; gemcitabin; cisplatin; radiotherapy; drug therapy; combination
分类号:
R817.5
摘要:
放射性核素治疗在临床上主要以一种单一的方法在使用,很少作为治疗规范有效地与化学治疗、免疫治疗或者放射治疗联合应用。转移性骨肿瘤的疼痛缓解是近来放射性核素治疗的重要领域,89Sr是常用的治疗这种疾病的放射性核素,它与阿霉素、吉西他滨和顺铂等化疗药物或者放射治疗联合应用后可以增强放射性核素的治疗作用,延长疼痛缓解的时间。这种联合治疗的方法也被用来治疗淋巴瘤、神经母细胞瘤和脑胶质瘤等其他恶性肿瘤,显示出良好的应用前景。
Abstract:
Mostly radionuclide therapy was used as a sole method in clinical practice and seldom combined with chemotherapy, immunotherapy or radiotherapy as a treatment procotol. Pain palliation of bone metastases has become a main field in radionuclide therapy in the recent years and strontium-89 is a main radionuclide clinically used. Combining with chemotherapy, doxorubicin, gemcitabin, cisplatin, and radiotherapy can enhance the affect of radionuclide therapy and prolong the period of pain palliation. This con-comitant method was used in the treatment of lymphoma, neuroblastoma and glioma and showed excellent prospect.

参考文献/References:

1 Valdes Olmos RA, Hoefnagel CA. Radionuclide therapy in oncology:the dawning of its concomitant use with other modalities[J]. Eur J Nucl Med, 2004, 31(7):929-931.
2 Tu SM, Delpassand ES, Jones D, et al. Strontium-89 conbines with doxorubicin Ⅰ the treatment of patients with androgen-independent prostate cancer[J]. Urol Oncol, 1996, 2(1):191-197.
3 Logothetis C, Tu SM, Navone N. Targeting prostate cancer bonemetastases[J]. Cancer, 2003, 97(3):785-788.
4 Tu SM, Millikan RE, Mengistu B, et al. Bone-targeted therapy for advanced androgen-independent carcinoma of the prostate:a randomized phase Ⅱ trial[J]. Lancer, 2001, 357(2):336-341.
5 Pagliaro LC, Delpassand ES, Williams D, et al. A phase Ⅰ/Ⅱ study of strontium-89 combined with gemcitabine in the treatment of patients with androgen independent prostate carcinoma and bone metastases[J]. Cancer, 2003, 97(12):2988-2994.
6 Mertens WC, Porter AT, Reid RH, et al. Strontium-89 and low dose infusion cisplatin for patients with hormone refractory prostate carcinoma metastatic to bone:a prelimary report[J]. J Nucl Med, 1992,33(8):1437-1443.
7 Sciuto R, Festa A, Rea S, et al. Effect of low-dose cisplatin on 89Sr therapy for painful bone metastases from prostate cancer:a randomized clinical trial[J]. J Nucl Med, 2002, 43(1):79-86.
8 Sciuto R, Maini CL, Tofani A, et al. Radiosensitization with low-dose carboplatin enhances pain palliation in radioisotope therapy with strontium-89[J]. Nucl Med Commun, 1996, 17(9):799-804.
9 Scitu R, Festa A, Tofani A, et al. Platinum compounds as radiosensitizers in strontium-89 metabolic radiotherapy[J]. Clin Ter, 1998, 149(921):43-47.
10 Smeland S, Erikstein B, Aas M, et al. Role of strontium-89 as adjuvant to palliative external beam radiotherapy is questionable:results of a double-blind randomized study[J]. Int J Radiat Oncol Biol Phys,2003, 56(5):1397-1404.
11 Porter AT, McEwan AJ, Powe JE, et al. Results of a randomized phase-Ⅲ trial to evaluate the efficacy of strontium-89 adjuvant to local field ecternal beam irradiation in the management of endocrine resistant metastatic prostate cancer[J]. Int J Radiat Oncol Biol Phys,1993, 25(5):805-813.

相似文献/References:

[1]陈立,陈跃.分化型甲状腺癌骨转移诊断及疗效评价的核素显像研究进展[J].国际放射医学核医学杂志,2016,40(6):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
　Chen Li,Chen Yue.Diagnosis and evaluation of curative effect progress of radionuclide imaging methods in differentiated thyroid cancer of bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2016,40(2):452.[doi:10.3760/cma.j.issn.1673-4114.2016.06.010]
[2]郑玉明,程霞,郑棒.自制90Sr保持架在皮肤病敷贴治疗中的辐射防护作用[J].国际放射医学核医学杂志,2014,38(1):19.[doi:10.3760/cma.j.issn 1673-4114.2014.01.005]
　Zheng Yuming,Cheng Xia,Zheng Bang.Effects of serf-made 90Sr applicator retainer on radiation protection in treatment of skin disease[J].International Journal of Radiation Medicine and Nuclear Medicine,2014,38(2):19.[doi:10.3760/cma.j.issn 1673-4114.2014.01.005]
[3]袁超,李卫鹏,胡永全,等.89Sr治疗乳腺癌和前列腺癌多发性骨转移的临床观察[J].国际放射医学核医学杂志,2010,34(4):220.[doi:10.3760/cma.j.issn.1673-4114.2010.04.008]
　YUAN Chao,LI Wei-peng,HU Yong-quan,et al.Clinical observation of 89Sr treatment efficacy of multiple bone metastases in breast and prostate cancer patients[J].International Journal of Radiation Medicine and Nuclear Medicine,2010,34(2):220.[doi:10.3760/cma.j.issn.1673-4114.2010.04.008]
[4]何建华,喻文才.89SrCl2与153Sm-乙二胺四亚甲基膦酸治疗骨转移癌的对比研究[J].国际放射医学核医学杂志,2009,33(2):86.[doi:10.3760/cma.j.issn.1673-4114.2009.02.007]
　HE Jian-hua,YU Wen-cai.Comparison of treatment with 89SrCl2 and 153Sm-ethylenediaminetetramethylene phosphate in metastatic cancers of bone[J].International Journal of Radiation Medicine and Nuclear Medicine,2009,33(2):86.[doi:10.3760/cma.j.issn.1673-4114.2009.02.007]
[5]青春,邓候富,贾志云.放射性核素89Sr治疗骨转移癌的新进展[J].国际放射医学核医学杂志,2007,31(3):160.
　QING Chun,DENG Hou-fu,JIA Zhi-yun.The new advances of radionuclide 89Sr in metastatic bone cancer[J].International Journal of Radiation Medicine and Nuclear Medicine,2007,31(2):160.
[6]曹井旭,唐谨.靶性放射性核素治疗骨转移[J].国际放射医学核医学杂志,1995,19(4):153.
[7]李宁,柴华,杨志,等.唑来膦酸联合89Sr治疗前列腺癌骨转移的临床疗效[J].国际放射医学核医学杂志,2017,41(4):247.[doi:10.3760/cma.j.issn.1673-4114.2017.04.003]
　Li Ning,Chai Hua,Yang Zhi,et al.Clinical observation of zoledronic acid combined with 89Sr in the treatment of prostate cancer patients with bone metastases[J].International Journal of Radiation Medicine and Nuclear Medicine,2017,41(2):247.[doi:10.3760/cma.j.issn.1673-4114.2017.04.003]

备注/Memo

备注/Memo:
收稿日期:2004-11-17。
更新日期/Last Update: 1900-01-01